


Patent Docket P0894P1D2C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Joffre Baker et al. Serial No.: 09/896,856 Filed: 29 June 2001 For: CARDIAC HYPERTROPHY FACTOR AND USES THEREFOR	Group Art Unit: not yet assigned Examiner: not yet assigned CERTIFICATE UNDER 37 CFR 1.10 EL 142012563 US: Express Mail I hereby certify that this correspondence and related documents is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patent and Trademarks, Washington, D.C. 20231 January 18, 2002  Yvonne Carter
--	---

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING
UNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 08/733,850 be used as the computer-readable Sequence Listing for the present, above-identified application.


The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 08/733,850 .

Respectfully submitted,

GENENTECH, INC.

Date: January 18, 2002

By:



Deirdre L. Conley, Ph.D.

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE
Doc. #103446

- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).


In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: January 18, 2002

By:


Deirdre L. Conley, Ph.D.

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

Doc. 103523